Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients.
Pneumocystis carinii pneumonia continues to be a cause of morbidity and mortality in AIDS patients. Current therapies have a high rate of toxicity and failure. Compound 566C80 is a 1-4,hydroxynaphthoquinone with potent antiprotozoal activity which shows good efficacy and safety in 21-day treatment trials of P. carinii pneumonia (PCP) in AIDS patients. Because there is a generally high recurrence rate after treatment of PCP and there may be a possible advantage in decreasing the P. carinii burden in the lung with extended anti-Pneumocystis therapy, we performed an open label-trial of the safety and efficacy of 42-day therapy with 566C80 for PCP in AIDS patients. Ten patients were enrolled and one was lost to follow-up. Eight of the remaining nine patients successfully completed 42 days of therapy with minimal toxicity. This trial suggests that 566C80 for 42 days can be an effective, safe, and well-tolerated oral therapy for PCP in AIDS patients.
Dohn
M N
MN
University of Cincinnati Medical Center, Ohio 45267-0564.
Frame
P T
PT
Baughman
R P
RP
Lafon
S W
SW
Smulian
A G
AG
Caldwell
P
P
Rogers
M D
MD
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000284:Administration, Oral; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053626:Atovaquone; D001992:Bronchoalveolar Lavage Fluid; D004361:Drug Tolerance; D005500:Follow-Up Studies; D005502:Food; D006801:Humans; D008297:Male; D009285:Naphthoquinones / Q000009:adverse effects / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy*; D012008:Recurrence; D013997:Time Factors
D000935:Antifungal Agents; D009285:Naphthoquinones; D053626:Atovaquone